Population science, systems biology, oncogenesis, tumor virology and immunology, autophagy, drug development and resistance, cancer control and prevention, bioinformatics, cancer genomics, and the relationship between cellular and genetic alterations and tumor development.
As New Jersey’s only National Cancer Institute-designated comprehensive cancer center, Rutgers Cancer Institute is dedicated to improving the prevention, detection, treatment and care of cancer patients. It seeks to accomplish this by turning laboratory discoveries into clinical practice. The center is noted for delivering advanced comprehensive care. Inpatients receive treatment at any of 17 New Jersey hospitals, but chiefly 610-bed Robert Wood Johnson University Hospital, to which U.S. News & World Report gives a “Best Hospitals” cancer-care score of 49.6/100. The institute also is known for offering access to clinical trials and conducting cutting-edge cancer research. Research programs include cell death and survival signaling, genomic instability and tumor progression, cancer pharmacology and preclinical therapeutics, clinical investigations, carcinogenesis and chemoprevention, and cancer prevention and control. The institute collaborates with New Jersey’s universities, and pharmaceutical and biotechnology companies — this facilitates a swift pace of bringing breakthrough discoveries to patients.